[Indomethacin in rheumatic diseases with special reference to ophthalmologic studies].
D000493:Allopurinol / Q000009:adverse effects / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001379:Azathioprine / Q000009:adverse effects / Q000627:therapeutic use; D001773:Blood Cells / Q000187:drug effects; D002214:Capsules; D002986:Clinical Trials as Topic; D005128:Eye Diseases / Q000139:chemically induced*; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006073:Gout / Q000188:drug therapy; D006801:Humans; D007213:Indomethacin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D012216:Rheumatic Diseases / Q000188:drug therapy*; D012595:Scleroderma, Systemic / Q000188:drug therapy; D013167:Spondylitis, Ankylosing / Q000188:drug therapy; D013488:Suppositories
D002214:Capsules; D013488:Suppositories; D000493:Allopurinol; D001379:Azathioprine; D007213:Indomethacin
Indometacin Bei Erkrankungen des rheumatischen formenkreises unter Berücksichtigung ophthalmologischer Untersuchungen.